...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging
【24h】

In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging

机译:在基于报道基因的MR成像中,在体内跟踪间充质干细胞对恶性胶质瘤的热感

获取原文
获取原文并翻译 | 示例

摘要

Mesenchymal stem cells (MSCs) have emerged as a promising cellular vehicle for gene therapy of malignant gliomas due to their property of tumor tropism. However, MSCs may show bidirectional and divergent effects on tumor growth. Therefore, a robust surveillance system with a capacity for noninvasive monitoring of the homing, distribution and fate of stem cells in vivo is highly desired for developing stem cell-based gene therapies for tumors. In this study, we used ferritin gene-based magnetic resonance imaging (MRI) to track the tumor tropism of MSCs in a rat orthotopic xenograft model of malignant glioma. MSCs were transduced with lentiviral vectors expressing ferritin heavy chain (FTH) and enhanced green fluorescent protein (eGFP). Intra-arterial, intravenous and intertumoral injections of these FTH transgenic MSCs (FTH-MSCs) were performed in rats bearing intracranial orthotopic C6 gliomas. The FTH-MSCs were detected as hypointense signals on T2- and T2*-weighted images on a 3.0 T clinical MRI. After intra-arterial injection, 17% of FTH-MSCs migrated toward the tumor and gradually diffused throughout the orthotopic glioma. This dynamic process could be tracked in vivo by MRI up to 10 days of follow-up, as confirmed by histology. Moreover, the tumor tropism of MSCs showed no appreciable impact on the progression of the tumor. These results suggest that FTH reporter gene-based MRI can be used to reliably track the tropism and fate of MSCs after their systemic transplantation in orthotopic gliomas. This real-time in vivo tracking system will facilitate the future development of stem cell-based therapies for malignant gliomas.
机译:间充质干细胞(MSCs)由于其肿瘤热性的性质而出现为恶性胶质瘤的基因治疗的有前途的细胞载体。然而,MSCs可以对肿瘤生长显示双向和发散影响。因此,对于发育基于干细胞的基因疗法,强烈需要具有非侵入性监测的具有非侵入性监测能力的强大监测系统,用于发育基于干细胞的肿瘤的基因疗法。在该研究中,我们使用铁蛋白基因的磁共振成像(MRI)来跟踪MSCs在恶性胶质瘤大鼠原位异种移植模型中的MSCs肿瘤。用表达铁蛋白重链(FTH)和增强的绿色荧光蛋白(EGFP)的慢病毒载体转导MSC。在轴承颅内原位C6胶质瘤的大鼠中进行这些FTH转基因MSCs(FTH-MSCs)的动脉内,静脉内和间际注射。在3.0T临床MRI上检测到FTH-MSCs在T2和T2 * -weighted图像上被检测为低音信号。在动脉内注射后,17%的FTH-MSCs朝向肿瘤迁移并逐渐扩散在整个原位胶质瘤。该动态过程可以通过MRI在体内跟踪,后续10天,通过组织学确认。此外,MSCs的肿瘤热衷于对肿瘤的进展没有明显影响。这些结果表明,在原位胶质瘤的系统移植后,可以使用基于第五基因基因的MRI来可靠地跟踪MSCs的矫正和命运。体内跟踪系统中的这一实时将有助于对恶性胶质瘤的基于干细胞的疗法的未来发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号